Routes of
administration Intravenous PubChem CID 53234134 Molar mass 666.689 g/mol | CAS Number 689293-68-3 Formula C23H30N12O8S2 | |
 | ||
Trade names Zerbaxa (with tazobactam) ATC code J01DI54 (WHO) (combination with β-lactamase inhibitor) Legal status US: Approved January 2015 | ||
Ceftolozane is a 5th generation cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that have become resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia. Ceftolozane is combined with the β-lactamase inhibitor tazobactam, which protects ceftolozane from degradation. Ceftolozane-tazobactam (trade name Zerbaxa) is indicated for the treatment of complicated urinary tract infections and complicated intra abdominal infections.
Spectrum of activity
The in vitro activity of ceftolozane–tazobactam has been examined in five surveillance studies of isolates from Europe and North America. In these studies, ceftolozane–tazobactam was notable for its activity against Pseudomonas aeruginosa, a moderately common cause of hospital-acquired infections that is commonly multi-drug resistant. Ninety percent of P. aeruginosa isolates were inhibited by a ceftolozane–tazobactam at a concentration of 4 μg/mL (MIC90), making it the most potent anti-pseudomonal antibiotic in clinical use.
In these same studies, ceftolozane–tazobactam exhibited MIC90 values of <1 μg/mL for Escherichia coli, Citrobacter koseri, Morganella morganii, Proteus mirabilis, Salmonella species, and Serratia marcescens. Somewhat poorer activity is observed for the Klebsiella and Enterobacter species, with the MIC90 for extended spectrum beta-lactamase (ESBL) expressing Klebsiella pneumonia being >32 μg/mL.